2026年3月最新《新锐期刊分区表》数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
体验更多LetPub AI科研工具 >> | |
| 近期推荐： | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 新 聚合物期刊JPM征稿｜IF持续上升 + APC折扣 | 热 Springer Nature特刊征稿 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | CANCER CANCER-AM CANCER SOC （此期刊被最新的JCR期刊SCIE收录） LetPub评分 8.0
59人评分
我要评分
声誉 8.8 影响力 7.4 速度 7.8 | |||||||||||||||||||||
| 期刊ISSN | 0008-543X | 安装APP，查看期刊最新消息
| ||||||||||||||||||||
| E-ISSN | 1097-0142 | |||||||||||||||||||||
| 2024-2025最新影响因子 （数据来源于搜索引擎） | 5.1 点击查看影响因子趋势图 | |||||||||||||||||||||
| 实时影响因子 | 截止2026年5月06日：5.6 | |||||||||||||||||||||
| 2024-2025自引率 | 2.0%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年影响因子 | 6.3 | |||||||||||||||||||||
| JCI期刊引文指标 | 1.2 | |||||||||||||||||||||
| h-index | 277 | |||||||||||||||||||||
| CiteScore （ 2025年最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0142 | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | https://mc.manuscriptcentral.com/cancer | |||||||||||||||||||||
| 该期刊中国学者近期发文 - New | Poor clinical outcomes and immunoevasive contexture in gastric cancer patients bearing p16 high phenotype Author: Wang, Jieti; Gu, Yun; Zhang, Ziqiu; Ling, Zhen; Lin, Chao; Liu, Hao; Li, Ruochen; He, Hongyong; Shao, Fei; Xu, Jiejie Journal: CANCER. 2026; Vol. 132, Issue 6, pp. -. DOI: 10.1002/cncr.70363 Durvalumab combined with concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer: A prospective, single-arm, phase 2 clinical trial Author: Song, Chunyang; Zhao, Xiaohan; Li, Shuguang; Guo, Xuehan; Zhang, Xueyuan; Wang, Xiaobin; Li, Youmei; Yan, Ke; Su, Jingwei; Xu, Jinrui; Zhu, Shuchai; Shen, Wenbin Journal: CANCER. 2026; Vol. 132, Issue 6, pp. -. DOI: 10.1002/cncr.70351 Long-term outcomes of newly diagnosed POEMS syndrome patients treated with bortezomib-based therapies Author: He, Haiyan; Fu, Qingcheng; Yu, Xuerou; Chen, Xi; Lu, Jing; Jin, Lina; Fan, Xiaoqiang; Du, Juan Journal: CANCER. 2026; Vol. 132, Issue 4, pp. -. DOI: 10.1002/cncr.70293 T-cell receptor-like chimeric antigen receptor T cells targeting mesothelin: A first-in-human dose-escalation trial for platinum-resistant advanced ovarian cancer Author: Shan, Yiyang; Ding, Bo; Ji, Feng; Lin, Hao; Shi, Weiwei; Wang, Enxiu; Wang, Chen; Shen, Yang Journal: CANCER. 2026; Vol. 132, Issue 3, pp. -. DOI: 10.1002/cncr.70279 | |||||||||||||||||||||
| 期刊语言要求 | Language Manuscripts must be written in American English and be grammatically and linguistically correct. Authors should seek assistance with style, grammar and vocabulary if necessary. Your manuscript may also be sent back to you for revision if the quality of English language is poor. 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足CANCER的语言要求，还能让CANCER编辑和审稿人得到更好的审稿体验，让稿件最大限度地被CANCER编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, USA, NJ, 07030 | |||||||||||||||||||||
| 出版商 | John Wiley and Sons Inc. | |||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Semimonthly | |||||||||||||||||||||
| 出版年份 | 0 | |||||||||||||||||||||
| 年文章数 | 300点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 24.93% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 92.67% | |||||||||||||||||||||
| WOS期刊JCR分区 （ 2024-2025年最新版） | WOS分区等级：1区
| |||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） |
| |||||||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0008-543X%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 很快,2-3周 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 较易 | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在CANCER顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Poor clinical outcomes and immunoevasive contexture in gastric cancer patients bearing p16 high phenotype Author: Wang, Jieti; Gu, Yun; Zhang, Ziqiu; Ling, Zhen; Lin, Chao; Liu, Hao; Li, Ruochen; He, Hongyong; Shao, Fei; Xu, Jiejie Journal: CANCER. 2026; Vol. 132, Issue 6, pp. -. DOI: 10.1002/cncr.70363 PubMed DOI |
| 2. | Durvalumab combined with concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer: A prospective, single-arm, phase 2 clinical trial Author: Song, Chunyang; Zhao, Xiaohan; Li, Shuguang; Guo, Xuehan; Zhang, Xueyuan; Wang, Xiaobin; Li, Youmei; Yan, Ke; Su, Jingwei; Xu, Jinrui; Zhu, Shuchai; Shen, Wenbin Journal: CANCER. 2026; Vol. 132, Issue 6, pp. -. DOI: 10.1002/cncr.70351 PubMed DOI |
| 3. | Long-term outcomes of newly diagnosed POEMS syndrome patients treated with bortezomib-based therapies Author: He, Haiyan; Fu, Qingcheng; Yu, Xuerou; Chen, Xi; Lu, Jing; Jin, Lina; Fan, Xiaoqiang; Du, Juan Journal: CANCER. 2026; Vol. 132, Issue 4, pp. -. DOI: 10.1002/cncr.70293 PubMed DOI |
| 4. | T-cell receptor-like chimeric antigen receptor T cells targeting mesothelin: A first-in-human dose-escalation trial for platinum-resistant advanced ovarian cancer Author: Shan, Yiyang; Ding, Bo; Ji, Feng; Lin, Hao; Shi, Weiwei; Wang, Enxiu; Wang, Chen; Shen, Yang Journal: CANCER. 2026; Vol. 132, Issue 3, pp. -. DOI: 10.1002/cncr.70279 PubMed DOI |
| 5. | The evolution and prognostic impact of HER2-low, HER2-ultralow, and HER2-null status in HER2-negative early breast cancer: A pre- to post-neoadjuvant chemotherapy study Author: Qiu, Yibin; Wu, Long; Cai, Weifeng; Chen, Minyan; Jiang, Meichen; Wang, Yali; Liu, Shunyi; He, Peng; Lin, Yuxiang; Chen, Lili; Yang, Yinghong; Wang, Chuan; Zhang, Jie; Fu, Fangmeng Journal: CANCER. 2026; Vol. 132, Issue 3, pp. -. DOI: 10.1002/cncr.70269 PubMed DOI |
| 6. | The safety of trastuzumab deruxtecan (T-DXd) in breast cancer brain metastases with a focus on interstitial lung disease/pneumonitis: A systematic review and meta-analysis Author: Ma, Yiwen; Li, Xiaorui; Jiang, Yujun; Xiao, Liping; Sun, Tao Journal: CANCER. 2026; Vol. 132, Issue 3, pp. -. DOI: 10.1002/cncr.70268 PubMed DOI |
| 7. | Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A cost-effectiveness analysis Author: Luo, Jiefeng; Li, Zhengxiong; Ge, Jun; Cai, Sizhen; Mo, Xinyi; Liu, Wensheng; Gui, Chengxia; Du, Qiong; Liu, Jiyong Journal: CANCER. 2026; Vol. 132, Issue 3, pp. -. DOI: 10.1002/cncr.70259 PubMed DOI |
| 8. | Tebotelimab plus niraparib in previously treated locally advanced or metastatic solid tumors: A phase 1b dose escalation and expansion study Author: Qiu, Miao-Zhen; Pan, Hongming; Lam, Ka On; Wang, Jufeng; Zheng, Yi; Li, Huiping; Wu, Xinhong; Wang, Li; Bao, Lequn; Cheng, Jing; Shi, Yanxia; Gao, Yunong; Yan, Min; Luo, Huiyan; Zheng, Yu; Zhen, Xiaoa; Hang, Wenzhao; Hou, Jianmei; Xu, Rui-Hua Journal: CANCER. 2025; Vol. 131, Issue 11, pp. -. DOI: 10.1002/cncr.35919 PubMed DOI |
| 9. | Insights and recommendations for pain and nonopioid use in patients with cancer Author: Zhou, Wenjianbin; Xu, Shenghao Journal: CANCER. 2025; Vol. 131, Issue 10, pp. -. DOI: 10.1002/cncr.35902 PubMed DOI |
| 10. | Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum-based treatment: A phase 1/2 trial Author: Shou, Jiawei; Chen, Jun; Guo, Qunyi; Hong, Wei; Wang, Yonghui; Rao, Chuangzhou; Lu, Liqin; Yang, Xinmei; Zhu, Dan; Lan, Fen; Fang, Yong; Pan, Hongming Journal: CANCER. 2025; Vol. 131, Issue 10, pp. -. DOI: 10.1002/cncr.35822 PubMed DOI |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共108条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
